TMI views this as one of the last steps to be able to implement its system in the LTAC market. With more than 700 LTAC’s across the US, TMI anticipates in excess of revenues that could exceed more than 1 million dollars per month from this segment of the marketplace.

TMI plans to use its technology with the nurses on call to monitor and help diagnose any change in the patient’s tissue around the specified areas.

The Beta Test is scheduled to run for 90 days. During this period, images are expected to be captured of existing patients on a time schedule, as well as any new patient admitted to the facility will also be imaged.

The data that will be compiled will be used to determine the type of specific care for the patient, as well as to demonstrate the practical use of the TMI System within the workplace.